|Bid||143.50 x 200|
|Ask||147.40 x 1500|
|Day's Range||143.27 - 147.54|
|52 Week Range||95.80 - 163.75|
|PE Ratio (TTM)||22.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.
In its Tones-2 study, JAZZ studied the efficacy and safety of JZP-110 to control excessive sleepiness in narcolepsy patients over a period of 12 weeks.
A 9-mg dose of JAZZ's Xyrem, which contains 1,640 mg of sodium, has caused physicians to be reluctant to prescribe the drug to ~20% of their patients.